Ivermectin Versus Albendazole for Chronic Strongyloidiasis

Mahidol University

Status and phase: Completed; Phase 3

Conditions: Chronic Strongyloidiasis

Treatments: Drug: Ivermectin; Drug: ivermectin; Drug: Albendazole

Study type: Interventional

Funder types: Other

Identifiers

NCT00765024

TM001-2008

Details and patient eligibility

About

A prospective controlled trial to compare the efficacy and safety of 7-day albendazole, single dose ivermectin, and 2-single dose ivermectin in 72 patients with chronic strongyloidiasis will be conducted at Siriraj Hospital, Bangkok, Thailand.

Enrollment: 90 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with positive strongyloides larva in the stool

Exclusion criteria

• Pregnancy
• Lactating women
• Known allergy to any study drug

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

90 participants in 3 patient groups

Albendazole

Active Comparator group

Description:

Albendazole for 7 days

Treatment:

Drug: Albendazole

ivermectin

Experimental group

Description:

ivermectin 200 mcg/kg single dose

Treatment:

Drug: Ivermectin

ivermectin 2 doses

Experimental group

Description:

ivermectin 200 mcg/kg two doses in 2 weeks

Treatment:

Drug: ivermectin